14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FLR vs ACA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FLR vs ACA. Trailing 12-month operating profitability (FLR 2.1% vs ACA 12.3%) and valuation multiples (FLR 14.9x vs ACA 29.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Engineering & Construction value chain with $7.3B market capitalization and 12.3% operating margin.
OpEx & R&D Reinvestment10.5% of Rev ($125M)
90D Engineering Disclosures0 Published
Investor FAQ FLR vs ACA Key Questions & Quantitative Answers
As of Nov 16, 2026, Arcosa, Inc. (ACA) is the stronger overall head-to-head candidate over Fluor Corporation (FLR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). FLR carries a Unified Composite Score of 43.3/100 (HOLD) at $48.20 (14.9x Forward P/E, 2.1% operating margin), whereas ACA carries 60.0/100 (BUY) at $149.15 (29.1x Forward P/E, 12.3% operating margin). Technically, FLR sits in a Neutral phase (RSI 49.1, CONSOLIDATION options structure) and ACA sits in a Markup phase (RSI 82.2, UNCLASSIFIED options structure).
FLR leads the Growth & Scale pillar: FLR posts +10.5% YoY revenue growth and -94.5% YoY earnings growth on $15.9B TTM revenue (3.3% gross margin, 2.1% operating margin), compared with ACA at +1.7% YoY revenue growth and +448.6% YoY earnings growth on $1.19B TTM revenue (22.8% gross margin, 12.3% operating margin). On trailing 12-month operating scale, FLR generates $15.9B in USD-normalized revenue versus $1.19B for ACA. In operating R&D and SG&A reinvestment, FLR deploys 1.2% of Rev ($191M) (0 90-day corporate R&D disclosures) versus 10.5% of Rev ($125M) (0 disclosures) for ACA.
FLR screens cheaper on headline valuation multiples. FLR trades at 14.9x Forward P/E, 15.7x Trailing P/E, 0.31x PEG, and 0.3x EV/Revenue (-2.7% FCF margin), whereas ACA trades at 29.1x Forward P/E, 36.4x Trailing P/E, 1.86x PEG, and 6.1x EV/Revenue (18.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FLR (-27.4% ROE) versus ACA (8.0% ROE) capital efficiency.
In options market volatility and institutional positioning, FLR carries 45.0% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.34x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.65β · 52% Vol realized risk). By comparison, ACA carries 28.7% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 4% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.